FDA evaluates orlistat
This article was originally published in The Tan Sheet
Executive Summary
FDA is evaluating "rare reports" of hepatitis and liver-related laboratory abnormalities in people taking orlistat - the active ingredient, at 60 mg, in GlaxoSmithKline's OTC weight-loss drug alli. "Because of a lack of information in the reports, at this time, it is not possible to know the degree to which orlistat is responsible for the reported liver problems," an FDA spokeswoman said in an e-mail June 4. The agency is working with GSK to obtain post-marketing safety adverse events associated with orlistat, she added. This evaluation of orlistat, which is also the active ingredient, at 120 mg, in Roche's prescription Rx diet drug Xenical, comes as FDA continues investigating whether adverse event reports of rectal bleeding signal a potential serious risk identified with the ingredient (1"The Tan Sheet" Feb. 9, 2009, p. 8)
You may also be interested in...
FDA Alerts Public To Ongoing Safety Review Of Orlistat In GSK, Roche Drugs
FDA's announcement it is investigating a possible risk of liver injury related to orlistat - the active ingredient in Roche Pharmaceuticals' prescription weight-loss drug Xenical and GlaxoSmithKline's OTC alli - could threaten short-term sales
FDA Alerts Public To Ongoing Safety Review Of Orlistat In GSK, Roche Drugs
FDA's announcement Aug. 24 that it is reviewing adverse event reports of liver injury related to orlistat - the active ingredient in GlaxoSmithKline's weight-loss product alli could threaten the drug's already slipping sales.
FDA Evaluating Orlistat For Potential Serious Risks
FDA is evaluating whether recent adverse event reports of rectal bleeding signal a potential serious risk identified with orlistat - the active ingredient in Roche's Rx diet drug Xenical and GlaxoSmithKline's OTC weight-loss product alli